HEYL and prostate adenocarcinoma: Kaplan-Meier analysis of the TCGA prostate adenocarcinoma (TCGA-PRAD) dataset indicated that patients with combined high expression of HeyL and CYP19A1 had lower disease-free survival rates than those with combined low expression of HeyL and CYP19A1. Moreover, the expression of both HeyL and aromatase was significantly increased in CRPC.